Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aspirin/alcohol mix not found to worsen upper GI hemorrhage in UCLA study -- AFA.

This article was originally published in The Tan Sheet

Executive Summary

ASPIRIN/ALCOHOL MIX NOT FOUND TO WORSEN UPPER GI HEMORRHAGE outcome or severity in 1,336 patients, according to an unpublished study by Dennis Jensen, MD, et al., UCLA and West Los Angeles V-A Medical Center, submitted by the Aspirin Foundation of America to FDA. AFA provided the agency with the results of the study, dated January 1998, as part of the industry group's comments on FDA's proposed rules requiring alcohol warnings for analgesic products. AFA continues to strongly oppose alcohol warnings for aspirin products, citing an absence of data proving the warnings to be necessary. AFA's comments were submitted by the D.C. firm Paul, Hastings, Janofsky & Walker. The public comment period ended Jan. 28.

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS051363

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel